Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Cancer
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 1000 results found since Jan 2013.
Simultaneous nanocarrier-mediated delivery of siRNAs and chemotherapeutic agents in cancer therapy and diagnosis: Recent advances
Eur J Pharmacol. 2021 Dec 14:174639. doi: 10.1016/j.ejphar.2021.174639. Online ahead of print.ABSTRACTRecently, investigations have revealed that RNA interference (RNAi) has a remarkable potential to decrease cancer burden by downregulating genes. Among various RNAi molecules, small interfering RNA (siRNA) has been more attractive for this goal and is able to silence a target pathological path and promote the degradation of a certain mRNA, resulting in either gain or loss of function of proteins. Moreover, therapeutic siRNAs have exhibited low side effects compared to other therapeutic molecular candidates. Nevertheless, s...
Source: European Journal of Pharmacology - December 17, 2021 Category: Drugs & Pharmacology Authors: Negar Bidar Majid Darroudi Ailin Ebrahimzadeh Mohammadreza Safdari Miguel de la Guardia Behzad Baradaran Vahabodin Goodarzi Fatemeh Oroojalian Ahad Mokhtarzadeh Source Type: research
EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects
Biomed Pharmacother. 2021 Dec 11;146:112532. doi: 10.1016/j.biopha.2021.112532. Online ahead of print.ABSTRACTBrain tumors are responsible for high mortality and morbidity worldwide. The brain tumor treatment depends on identification of molecular pathways involved in progression and malignancy. Enhancer of zeste homolog 2 (EZH2) has obtained much attention in recent years in field of cancer therapy due to its aberrant expression and capacity in modulating expression of genes by binding to their promoter and affecting methylation status. The present review focuses on EZH2 signaling in brain tumors including glioma, gliobla...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - December 15, 2021 Category: Drugs & Pharmacology Authors: Mahshid Deldar Abad Paskeh Atefeh Mehrabi Mohammad Hossein Gholami Amirhossein Zabolian Ehsan Ranjbar Hossein Saleki Adnan Ranjbar Mehrdad Hashemi Yavuz Nuri Ertas Kiavash Hushmandi Sepideh Mirzaei Milad Ashrafizadeh Ali Zarrabi Saeed Samarghandian Source Type: research
CD48-expressing non-small-cell lung cancer cells are susceptible to natural killer cell-mediated cytotoxicity
In this study, we showed that several NSCLC cell lines have differential sensitivity to NK cell-mediated cytotoxicity: NCI-H522 cells were highly sensitive, but A549, NCI-H23, NCI-H1915, and NCI-H1299 were resistant. Among activating ligands such as CD48, HLA-A/B/G, ICAM-1, MICA/B, and ULBPs, only CD48 rendered NCI-H522 cells susceptible to NK cell-mediated cytotoxicity, which was proved by using CD48 siRNA and neutralizing antibody. CD48-positive NCI-H522 cells established a more stable contact with NK cells than did CD48-negative A549 and CD48 siRNA cell-transfected NCI-H522 cells. Taken together, these data demonstrate ...
Source: Archives of Pharmacal Research - December 14, 2021 Category: Drugs & Pharmacology Authors: Eun Jae Park Hye Won Jun Ik Ho Na Hong Kyung Lee Jieun Yun Hyung Sook Kim Youngsoo Kim Jin Tae Hong Sang-Bae Han Source Type: research
Compound Kushen Injection Protects Skin From Radiation Injury via Regulating Bim
Conclusion: We conclude that CKI represents a promising radio-protective agent with a potential differential beneficial effect on both cancer cells (inducing apoptosis) and HSF cells (providing radio-protection via inhibiting IR-induced apoptosis), via regulating Bim. Our study uncovers a novel mechanism by which CKI inhibits human cancer cell while protects skin from radiotherapy, indicating CKI might be a promising radio-protective drug.Clinical Trial Registration: Chinese Clinical Trial Registry (www.chictr.org.cn), identifier ChiCTR2100049164.
Source: Frontiers in Pharmacology - December 9, 2021 Category: Drugs & Pharmacology Source Type: research
Docetaxel-triggered SIDT2/NOX4/JNK/HuR signaling axis is associated with TNF- α-mediated apoptosis of cancer cells
Biochem Pharmacol. 2021 Dec 2:114865. doi: 10.1016/j.bcp.2021.114865. Online ahead of print.ABSTRACTPrevious studies have confirmed that docetaxel (DTX) treatment increases TNF-α production in cancer cells, but its mechanism of action remains unclear. Therefore, this study aimed to determine the signaling axis by which DTX induced the expression of TNF-α in U937 leukemia and MCF-7 breast carcinoma cells. DTX treatment promoted Ca2+-controlled autophagy and SIDT2 expression, resulting in lysosomal degradation of miR-25 in U937 cells. Downregulation of miR-25 increased NOX4 mRNA stability and protein expression. NOX4-stimu...
Source: Biochemical Pharmacology - December 5, 2021 Category: Drugs & Pharmacology Authors: Liang-Jun Wang Jing-Ting Chiou Yuan-Chin Lee Long-Sen Chang Source Type: research
Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study
Biomed Pharmacother. 2021 Nov 30:112370. doi: 10.1016/j.biopha.2021.112370. Online ahead of print.ABSTRACTAIMS: Besides suppressing anti-tumoral immune responses, tumor-intrinsic inhibitory immune checkpoints have been implicated in tumor development. Herein, we aimed to investigate the significance of tumor-intrinsic CD73, as an inhibitory immune checkpoint, in non-small cell lung cancer (NSCLC) development and propose a novel therapeutic approach.MAIN METHODS: We investigated the cell viability, chemosensitivity, apoptosis, migration, and the cell cycle of A-549 and NCI-H1299 following treatment with cisplatin and CD73-s...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - December 4, 2021 Category: Drugs & Pharmacology Authors: Elham Baghbani Saeed Noorolyai Shima Rahmani Dariush Shanehbandi Mahdi Abdoli Shadbad Leili Aghebati-Maleki Ahad Mokhtarzadeh Oronzo Brunetti Rossella Fasano Nicola Silvestris Behzad Baradaran Source Type: research
